GeneDx (NASDAQ:WGS) CEO Sells $638,145.77 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total transaction of $638,145.77. Following the completion of the transaction, the chief executive officer owned 104,372 shares in the company, valued at approximately $6,342,686.44. This trade represents a 9.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, June 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The stock was sold at an average price of $53.77, for a total transaction of $195,669.03.
• On Wednesday, April 29th, Katherine Stueland sold 2,172 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total value of $141,592.68.
• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The shares were sold at an average price of $63.17, for a total value of $2,964,757.61.

GeneDx Price Performance

GeneDx stock opened at $59.01 on Friday. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -22.02 and a beta of 1.96. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87. The stock’s 50 day moving average is $54.25 and its 200-day moving average is $86.49.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The firm had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the previous year, the business posted ($0.23) earnings per share. Equities research analysts expect that GeneDx Holdings Corp. will post -1 EPS for the current year.

Hedge Funds Weigh In On GeneDx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in shares of GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after purchasing an additional 52,322 shares in the last quarter. Vanguard Group Inc. raised its stake in GeneDx by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock valued at $154,650,000 after purchasing an additional 18,647 shares in the last quarter. Franklin Resources Inc. raised its stake in GeneDx by 60.4% in the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after purchasing an additional 411,607 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in GeneDx by 87.1% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock valued at $132,435,000 after purchasing an additional 474,167 shares in the last quarter. Finally, Invesco Ltd. lifted its position in GeneDx by 59.2% during the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Multiple law firms are advertising a securities class action against GeneDx, with a lead-plaintiff deadline of August 3, 2026, alleging material misstatements and omissions about the viability of the Fabric Genomics acquisition. GeneDx securities fraud class action lawsuit filed
• Negative Sentiment: Several follow-up notices emphasize the alleged 49% stock decline after GeneDx’s Q1 2026 earnings report and a 94% write-off related to the acquisition, reinforcing concerns about execution and disclosure risk. Hagens Berman class action alert
• Neutral Sentiment: GeneDx disclosed insider sales by CEO Katherine Stueland and CFO Kevin Feeley, but the filings say the shares were sold to cover tax withholding obligations tied to vesting equity awards, which makes the transactions less alarming on their own. CEO SEC filing CFO SEC filing
• Positive Sentiment: GeneDx appointed Mark Gardner as company president, a leadership move that could improve execution and strategic focus over time. GeneDx appoints new president

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on WGS shares. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Jefferies Financial Group set a $150.00 price target on shares of GeneDx in a research note on Monday, February 23rd. Craig Hallum reaffirmed a “buy” rating and set a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price objective on shares of GeneDx and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, Guggenheim cut their price objective on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $96.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.